Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlodipine added to deferoxamine and deferiprone for cardiac iron overload in thalassemia major
IRCT20190829044642N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amlodipine in beta thalassemia and iron overload (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoints: Serum ferritin level and Cardiac T2* MRI iron overload. Started Sep 2019; status: completed.
02
Drugs
amlodipine
03
Conditions
beta thalassemiairon overload
Beyond the preview
Go deeper on IRCT20190829044642N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190829044642N1.